Janux Therapeutics, Inc. (JANX)
JANXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$11.25
-0.2500 (-2.17%) today
Regular session, Nov 13, 11:18 AM ET
- Market cap
- $688.01m
- P/E
- –
- EPS, last 4 quarters
- $-1.59
- Dividend yield
- –
- Day range
- $11.17 to $11.49
- 52-week range
- $11.45 to $35.34
- Average volume
- –
- Previous close
- $11.50
Analysts
12 coveringBuy11 buy, 0 hold, 1 sell
Targets a year out average $30.80, +173.9% from here
Earnings
next estimate $-0.5200Next report
Dec 2025
+21.5%
Mar 2026
+22.0%
Jun 2026
-34.6%
Sep 2026
+24.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | $3.73m | $10.27m | $9.29m |
| Gross profit | – | $3.73m | $10.27m | $9.29m |
| Operating income | -$42.40m | -$34.21m | -$31.69m | -$31.26m |
| Net income | -$31.95m | -$24.36m | -$21.97m | -$21.57m |
News
8 latest- Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 5, 2026
- Notable Thursday Option Activity: SOLS, JANX, UCTTBNK Invest · Oct 29, 2026
- Ensign Group (ENSG) Beats Q3 Earnings EstimatesZacks · Oct 27, 2026
- Notable Wednesday Option Activity: PANW, JANX, ASSTBNK Invest · Oct 21, 2026
- Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?Zacks · Sep 30, 2026
- The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux Zacks · Sep 16, 2026
- 4 Prostate Cancer Drug Stocks to Watch During Awareness MonthZacks · Sep 15, 2026
- Janux Therapeutics Doses First Patient In Phase 1 Study Of JANX013 RTTNews · Sep 14, 2026
The company
Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Janux's lead clinical candidate, JANX007, is a PSMA-targeted TRACTr being investigated in a Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also advancing additional PSMA-targeted programs, including JANX014, a double-masked PSMA-TRACTr being evaluated in a Phase 1 clinical trial, and JANX013, a CD28 co-stimulatory TRACIr designed for combination with JANX007 and being evaluated in a Phase 1 clinical trial. Beyond its prostate cancer programs, Janux's pipeline includes JANX011, a CD19-targeted ARM being evaluated in a Phase 1 clinical trial in healthy adult volunteers for the potential treatment of autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- januxrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.